In an Italian study, Leonetti et al. [53] enrolled advanced EGFR-mutated NSCLC patients who were going through first- or second-line treatment with osimertinib from May 2018 to November 2022. This evidence concerns the gene EGFR and non-small cell lung carcinoma.